CDK4 and CDH1-related diffuse gastric and lobular breast cancer syndrome: Moreover, combined with endocrine therapy, CDK4/6 inhibitors (CDK4/6i) such as palbociclib, ribociclib, or abemaciclib are pivotal for targeting cell cycle progression in advanced LBC [4].